Creative Medical Technology Announces Peer-Reviewed Publication of Positive StemSpine® Study Results
–Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Events in Patients Who Underwent the StemSpine® Procedure for the Treatment of Chronic Low Back Pain —
PHOENIX, Sept. 26, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology and orthopedics, today announced the peer-reviewed publication , positive two-year follow-up data for the company’s StemSpine® study showing significant efficacy of StemSpine® treatment procedure for chronic low back pain without any serious adverse effects being reported.
The stem of the spine® The publication demonstrates the clinical use of the patented procedure that uses bone marrow aspiration from the patient for the treatment of chronic low back pain. There were no safety-related issues up to two years of follow-up. The stem of the spine® The procedure resulted in an 87% efficacy rate in treated patients in terms of decreased pain and increased mobility.
“The positive two-year data from our StemSpine® The study is very encouraging and may help alleviate the current opioid crisis related to prescription drug abuse for chronic lower back pain,” said Timothy Warbington, president and CEO of the company. “To our knowledge, this is the first demonstration of the clinical effectiveness of injecting bone marrow aspirate into areas surrounding the disc, which can repair, reshape and improve blood supply around the disc. disc and lumbar region.We believe that StemSpine® represents an attractive non-surgical option for many of the millions of Americans who suffer from chronic lower back pain and eagerly await further translation.
The stem of the spine® The patent also covers the use of ready-to-use (allogeneic) adult donor stem cells for this indication.
The publication can be viewed at www.creativemedicaltechnology.com.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a biotechnology company specializing in regenerative medicine in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. For more information about the Company, please visit www.creativemedicaltechnology.com.
Forward-looking statements
This press release may contain forward-looking statements, including, but not limited to, comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements relate to future events and conditions and, therefore, involve risks and uncertainties. Actual results may differ materially from those currently anticipated in these statements. See periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.
SOURCE Creative Medical Technology Holdings, Inc.
